Information | Article | Research Update | Safety | Clinical Study | FAQ | Long Term Study

6-OXO Safety

The following abstract was from a presentation given by Thomas Incledon, PhDc, RD, LD/LN, RPT, NSCA-CPT, CSCS at the American College of Nutrition 44th Annual Meeting, Nashville, TN. October 9-12, 2003.

THE CHRONIC EFFECTS OF ANDROST-4-ENE-3,6,17-TRIONE ON SAFETY MARKERES IN RESISTANCE-TRAINED MEN Incledon T. President, Human Performance Specialists, Inc., Chandler.
This study investigated the effects of a dietary supplement, androst-4ene-3,6,17-trione (also known as 3,6,17-androstenetrione or 6-keto-androstenedione - hereafter referred to as 6OXO) on serum clinical laboratory markers in six resistance-trained men. Our lab previously reported that the oral ingestion of 6OXO for three weeks can increase testosterone in resistance trained men, potentially via inhibition of the aromatase enzyme. Triglycerides, total cholesterol, HDL-C, LDL-C, albumin, glucose, BUN, creatinine, sodium, potassium, chloride, carbon dioxide, calcium, total protein, globulin, total bilirubin, ALP, ALT, AST, WBCs with differential, RBCs, MCV, MCHC, hematocrit, and hemoglobin. Results were analyzed using a univariate ANOVA design. The results indicated no significant effects on clinical markers except for significant decreases in total cholesterol (p< .001), HDL-C (p< .05), LDL-C (p< .001), ALP (p< .05), AST(p< .05), RDW(p< .05), and MCHC(p< .05). While the clinical markers were usually within normal limits, the results indicate the importance of monitoring clinical markers in subjects as part of an appropriate safety evaluation.

This study was funded by LPJ Research.

Information | Article | Research Update | Safety | Clinical Study | FAQ | Long Term Study